Vaccines for the elderly: current use and future challenges

Abstract Age-related changes of the immune system contribute to increased incidence and severity of infections in the elderly. Vaccination is the most effective measure to prevent infections and vaccination recommendations in most countries include specific guidelines for the elderly. Vaccination ag...

Full description

Bibliographic Details
Main Author: Birgit Weinberger
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Immunity & Ageing
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12979-017-0107-2
id doaj-8132afca14e64190a772a3865854c805
record_format Article
spelling doaj-8132afca14e64190a772a3865854c8052020-11-25T00:39:06ZengBMCImmunity & Ageing1742-49332018-01-011511810.1186/s12979-017-0107-2Vaccines for the elderly: current use and future challengesBirgit Weinberger0Universität Innsbruck, Institute for Biomedical Aging ResearchAbstract Age-related changes of the immune system contribute to increased incidence and severity of infections in the elderly. Vaccination is the most effective measure to prevent infections and vaccination recommendations in most countries include specific guidelines for the elderly. Vaccination against influenza and Streptococcus pneumoniae is usually recommended for persons with underlying diseases and for the elderly with heterogeneous age limits between ≥ 50 years and ≥ 65 years. Some countries also recommend vaccination against herpes zoster. Several vaccines are recommended for all adults, such as regular booster shots against tetanus/diphtheria/pertussis/polio, or for specific groups, e.g. vaccination against tick-borne encephalitis in endemic areas or travel vaccines. These are also relevant for the elderly. Most currently used vaccines are less immunogenic and effective in the elderly compared to younger adults. Potential strategies to improve their immunogenicity include higher antigen dose, alternative routes of administration, and the use of adjuvants, which were all implemented for influenza vaccines, and induce moderately higher antibody concentrations. Research on universal vaccines against influenza and S. pneumoniae is ongoing in order to overcome the limitations of the current strain-specific vaccines. Respiratory syncytial virus causes significant morbidity in the elderly. Novel vaccines against this and other pathogens, for instance bacterial nosocomial infections, have tremendous potential impact on health in old age and are intensively studied by many academic and commercial organizations. In addition to novel vaccine developments, it is crucial to increase awareness for the importance of vaccination beyond the pediatric setting, as vaccination coverage is still far from optimal for the older population.http://link.springer.com/article/10.1186/s12979-017-0107-2VaccineElderlyAgingImmunosenescenceInfluenzaHerpes zoster
collection DOAJ
language English
format Article
sources DOAJ
author Birgit Weinberger
spellingShingle Birgit Weinberger
Vaccines for the elderly: current use and future challenges
Immunity & Ageing
Vaccine
Elderly
Aging
Immunosenescence
Influenza
Herpes zoster
author_facet Birgit Weinberger
author_sort Birgit Weinberger
title Vaccines for the elderly: current use and future challenges
title_short Vaccines for the elderly: current use and future challenges
title_full Vaccines for the elderly: current use and future challenges
title_fullStr Vaccines for the elderly: current use and future challenges
title_full_unstemmed Vaccines for the elderly: current use and future challenges
title_sort vaccines for the elderly: current use and future challenges
publisher BMC
series Immunity & Ageing
issn 1742-4933
publishDate 2018-01-01
description Abstract Age-related changes of the immune system contribute to increased incidence and severity of infections in the elderly. Vaccination is the most effective measure to prevent infections and vaccination recommendations in most countries include specific guidelines for the elderly. Vaccination against influenza and Streptococcus pneumoniae is usually recommended for persons with underlying diseases and for the elderly with heterogeneous age limits between ≥ 50 years and ≥ 65 years. Some countries also recommend vaccination against herpes zoster. Several vaccines are recommended for all adults, such as regular booster shots against tetanus/diphtheria/pertussis/polio, or for specific groups, e.g. vaccination against tick-borne encephalitis in endemic areas or travel vaccines. These are also relevant for the elderly. Most currently used vaccines are less immunogenic and effective in the elderly compared to younger adults. Potential strategies to improve their immunogenicity include higher antigen dose, alternative routes of administration, and the use of adjuvants, which were all implemented for influenza vaccines, and induce moderately higher antibody concentrations. Research on universal vaccines against influenza and S. pneumoniae is ongoing in order to overcome the limitations of the current strain-specific vaccines. Respiratory syncytial virus causes significant morbidity in the elderly. Novel vaccines against this and other pathogens, for instance bacterial nosocomial infections, have tremendous potential impact on health in old age and are intensively studied by many academic and commercial organizations. In addition to novel vaccine developments, it is crucial to increase awareness for the importance of vaccination beyond the pediatric setting, as vaccination coverage is still far from optimal for the older population.
topic Vaccine
Elderly
Aging
Immunosenescence
Influenza
Herpes zoster
url http://link.springer.com/article/10.1186/s12979-017-0107-2
work_keys_str_mv AT birgitweinberger vaccinesfortheelderlycurrentuseandfuturechallenges
_version_ 1725295183609724928